4D Molecular Therapeutics Shifts Focus to Late-Stage Gene Therapy for Eye Disease

In a strategic move to prioritize its most promising clinical candidate, 4D Molecular Therapeutics has announced the discontinuation of two clinical programs and the cessation of funding for three additional assets. This decision allows the biotech company to reallocate its resources towards the development of 4D-150, a gene therapy aimed at treating eye disease, which is now entering late-stage clinical studies. The shift underscores the company's commitment to advancing innovative treatments for eye diseases, leveraging its expertise in gene therapy to address unmet medical needs in this area.